Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist. The drug and its active metabolite, ACT-333679, have a similar mode of action to the prostacyclin analogs, but with greater selectivity for the PGI2 receptor.
Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is positioned to become the second highest-selling drug behind Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) in the forecast period, with strong peak sales of $1.5bn across the forecast markets. Notably, Uptravi represents the first prostacyclin to launch for pulmonary hypertension (PH) supported by clinical data demonstrating a slowing of disease progression and reduced risk of hospitalization. Furthermore, it is dosed orally, eliminating the need for the burdensome injections or regular inhalation with other prostacyclins. This attractive clinical profile will allow Johnson & Johnson to expand the role of the prostacyclin class in the treatment of PH, which is typically reserved as a later-line therapy. Furthermore, Uptravi is being investigated in a triple combination regimen with a phosphodiesterase 5 (PDE5) inhibitor and Johnson & Johnson’s endothelin receptor antagonist (ERA) Opsumit. This may encourage physicians to treat newly diagnosed patients aggressively with improved outcomes, while consolidating both Uptravi and Opsumit as leaders within the PH market.
LIST OF FIGURES
11 Figure 1: Uptravi for pulmonary hypertension – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Uptravi for pulmonary hypertension
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Uptravi for pulmonary hypertension
15 Figure 4: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES 6 Table 1: Uptravi drug profile
7 Table 2: Uptravi pivotal trial data in pulmonary hypertension
9 Table 3: Uptravi ongoing late-phase trials in pulmonary hypertension
16 Table 4: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.